Mengran Lang

机构：Chinese Academy of Medical Sciences & Peking Union Medical College

发表论文 16 篇 · 总被引 140 次 · h-index 8

代表论文

• A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma (2023 · Journal of Hepatocellular Carcinoma · 被引 25)
• The past, present and future of conversion therapy for liver cancer. (2021 · PubMed · 被引 21)
• A novel evaluation benchmark for medical LLMs illuminating safety and effectiveness in clinical domains (2025 · npj Digital Medicine · 被引 15)
• Efficacy and safety of sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a two-center study in China (2022 · Journal of Gastrointestinal Oncology · 被引 13)
• Predictive Value of Preoperative Serum AFP, CEA, and CA19-9 Levels in Patients with Single Small Hepatocellular Carcinoma: Retrospective Study (2022 · Journal of Hepatocellular Carcinoma · 被引 12)
• Conversion of initially unresectable hepatocellular carcinoma (HCC) with triple-combination therapy (lenvatinib, anti-PD-1 antibodies, and transarterial therapy): A retrospective analysis. (2022 · Journal of Clinical Oncology · 被引 11)